HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway

Abstract Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, cetuximab stands out, but resistance to cetuximab frequently ar...

Full description

Saved in:
Bibliographic Details
Main Authors: Yunan Liang, Han Lin, Zongsheng Jiang, Qi Zhao, Ri Cui, Shaotang Li
Format: Article
Language:English
Published: Springer 2024-10-01
Series:Discover Oncology
Online Access:https://doi.org/10.1007/s12672-024-01440-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571588448354304
author Yunan Liang
Han Lin
Zongsheng Jiang
Qi Zhao
Ri Cui
Shaotang Li
author_facet Yunan Liang
Han Lin
Zongsheng Jiang
Qi Zhao
Ri Cui
Shaotang Li
author_sort Yunan Liang
collection DOAJ
description Abstract Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, cetuximab stands out, but resistance to cetuximab frequently arises in targeted treatments. Currently, the role of HOXB8 in cetuximab-resistant mCRC remains unclear. By comparing drug-sensitive cell lines (SW48) with drug-resistant cell lines (HCT116, CACO2), we discovered that HOXB8 was substantially expressed in cetuximab-resistant cell lines, and furthermore, in drug-resistant cell lines (HCT116, CACO2), HOXB8 knockdown increased the cytotoxicity of cetuximab via blocking the signal transducer and activator of transcription 3 (STAT3) signaling pathway. Conversely, the excessive expression of HOXB8 reduced the growth suppression in SW48 cells caused by cetuximab by triggering the STAT3 signaling pathway. Conclusively, we conclude that HOXB8 has played an essential role in cetuximab-resistant mCRC and that treating HOXB8 specifically may be a useful treatment approach for certain cetuximab-resistant mCRC patients.
format Article
id doaj-art-6d5d6705b4eb4f60ad64aeed2ea8d3fe
institution Kabale University
issn 2730-6011
language English
publishDate 2024-10-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-6d5d6705b4eb4f60ad64aeed2ea8d3fe2025-02-02T12:30:27ZengSpringerDiscover Oncology2730-60112024-10-0115111210.1007/s12672-024-01440-zHOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathwayYunan Liang0Han Lin1Zongsheng Jiang2Qi Zhao3Ri Cui4Shaotang Li5Department of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityDepartment of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityCancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical UniversityDepartment of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical UniversityAbstract Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, cetuximab stands out, but resistance to cetuximab frequently arises in targeted treatments. Currently, the role of HOXB8 in cetuximab-resistant mCRC remains unclear. By comparing drug-sensitive cell lines (SW48) with drug-resistant cell lines (HCT116, CACO2), we discovered that HOXB8 was substantially expressed in cetuximab-resistant cell lines, and furthermore, in drug-resistant cell lines (HCT116, CACO2), HOXB8 knockdown increased the cytotoxicity of cetuximab via blocking the signal transducer and activator of transcription 3 (STAT3) signaling pathway. Conversely, the excessive expression of HOXB8 reduced the growth suppression in SW48 cells caused by cetuximab by triggering the STAT3 signaling pathway. Conclusively, we conclude that HOXB8 has played an essential role in cetuximab-resistant mCRC and that treating HOXB8 specifically may be a useful treatment approach for certain cetuximab-resistant mCRC patients.https://doi.org/10.1007/s12672-024-01440-z
spellingShingle Yunan Liang
Han Lin
Zongsheng Jiang
Qi Zhao
Ri Cui
Shaotang Li
HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
Discover Oncology
title HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
title_full HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
title_fullStr HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
title_full_unstemmed HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
title_short HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway
title_sort hoxb8 mediates resistance to cetuximab in colorectal cancer cells through activation of the stat3 pathway
url https://doi.org/10.1007/s12672-024-01440-z
work_keys_str_mv AT yunanliang hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway
AT hanlin hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway
AT zongshengjiang hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway
AT qizhao hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway
AT ricui hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway
AT shaotangli hoxb8mediatesresistancetocetuximabincolorectalcancercellsthroughactivationofthestat3pathway